Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544331 | 0.94 | SIGMAR1 (0.40) | SIGMAR1MIF | |
| SCHEMBL2544025 | 0.89 | MIF (0.53) | SIGMAR1MIFTP53 | |
| SCHEMBL2542427 | 0.88 | SIGMAR1 (0.46) | SIGMAR1MIFTP53 | |
| SCHEMBL2546966 | 0.88 | TP53 (0.48) | MIFTP53 | |
| SCHEMBL2544322 | 0.87 | SLC6A2 (0.49) | SIGMAR1MIF | |
| SCHEMBL2543339 | 0.86 | TNIK (0.49) | MIFTNIKTSHR | |
| SCHEMBL2540868 | 0.85 | IDO1 (0.40) | SIGMAR1MIF | |
| SCHEMBL2540918 | 0.84 | POLB (0.54) | SIGMAR1MIFTSHRTP53 | |
| SCHEMBL2542689 | 0.83 | SIGMAR1 (0.54) | SIGMAR1TP53 | |
| SCHEMBL2542515 | 0.82 | ALDH1A1 (0.50) | MIFTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | SCHADT OLIVER | 2011-10-27 | — | — | US | claimed |
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | SCHADT OLIVER | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MET, RET, ERBB2 | SIGMAR1 3648/4885MIF 2143/4885TNIK 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.